To address a concern related to angiotensin-converting enzyme 2 (ACE2)-mediated SARS-CoV-2 invading, the RWE has demonstrated that antihypertensive drugs targeting the renin–angiotensin–aldosterone system do not raise the death rate of patients with the viral infection[36,40]. This evidence concerns the gene ACE2 and viral infectious disease.